US tests bomb that splits ships in half
The U.S. has successfully tested a lighter version of a bomb that can blast huge ships in half.
The U.S. Air Force (USAF) said Wednesday (June 4) they dropped a 500-pound QUICKSINK munition from a B-2 Spirit stealth bomber.
It follows a dramatic 2022 trial where a larger 2,000-pound variant was used to destroy a full-scale surface vessel.
The USAF say the smaller version of the precision-guided bomb offers a lower-cost anti-ship weapon, with more being able to be carried by bombers and fighter jets.
Col. Dan Lehoski, 53rd Wing commander, said: "QUICKSINK offers an affordable, game-changing solution to rapidly and efficiently sink maritime targets.
"AFRL's 500-pound QUICKSINK variant adds options for the warfighter and enhances operational flexibility."
The live-fire exercise was a collaborative effort between Air Force Materiel Command's Air Force Research Laboratory (AFRL) and Air Force Test Center and Air Combat Command's 53rd Wing.
Col. Matthew Caspers, AFRL Munitions Directorate commander, said: "QUICKSINK is the result of a Joint collaboration that rapidly prototyped an affordable concept for holding surface targets at risk."
It has not been reported what target the new variant was used against.
The post US tests bomb that splits ships in half appeared first on Talker.
Copyright Talker News. All Rights Reserved.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
20 hours ago
- Miami Herald
Military lasers blast drones from sky in groundbreaking test
By Dean Murray The US Army has conducted live-fire tests of laser weapons. Troops at Fort Sill in Oklahoma used armored transport-mounted directed energy (DE) to blast drones from the sky. The "first of its kind" exercise pitted prototype DE weapons, including a Directed Energy Maneuver Short-Range Air Defense (DE M-SHORAD) system, against a swarm of unmanned aircraft systems. The Army's pursuit of DE weapons for air defense stretches back decades, initially focused on strategic missile defense. However, the recent proliferation of inexpensive and readily available drones has shifted the focus to short-range air defense, where lasers and high-powered microwaves offer a potentially game-changing advantage. The US Army said: "This exercise provided a real-world test of the complementary nature of DE and kinetic systems, exploring how they can work together to create a more robust and resilient defense." Col. Steven D. Gutierrez, RCCTO Project Manager for Directed Energy, emphasised the groundbreaking nature of the exercise. "This live-fire exercise is the first of its kind. "Now that we have delivered directed energy capabilities to the Army, we are developing and maturing the domains of policy, doctrine, organisation, training, and personnel to employ the capability optimally." A US Army spokesperson said: "This exercise represents a crucial step forward, paving the way for a more agile and lethal force ready to meet the evolving challenges of modern warfare." The post Military lasers blast drones from sky in groundbreaking test appeared first on Talker. Copyright Talker News. All Rights Reserved.
Business Wire
2 days ago
- Business Wire
Momentus and Orbit Fab Partner to Advance Space Servicing with Podracer and RAFTI Demonstration Flight
SAN JOSE, Calif.--(BUSINESS WIRE)-- Momentus Inc. (NASDAQ: MNTS), a leading U.S. commercial space company specializing in satellite solutions, transportation, and in-space infrastructure, has signed a contract with Orbit Fab to provide hosted payload services for the on-orbit demonstration of Podracer, a space domain awareness payload, and the Rapidly Attachable Fluid Transfer Interface (RAFTI). The mission is scheduled to launch no earlier than February 2026 aboard a SpaceX Transporter rideshare mission. Fueling the future of space—Momentus and Orbit Fab demonstrates next-gen refueling and sensing technologies—delivering agile operations and mission resilience in orbit. Funded by the U.S. Air Force Research Laboratory (AFRL), Podracer will conduct a flight demonstration of infrared imaging sensors, image processing technology, and a control module to enhance space domain awareness aboard the Vigoride 7 orbital service vehicle (OSV). Podracer will also be used as part of a rendezvous and proximity operations (RPO) demonstration mission that Momentus plans to conduct during the Vigoride 7 mission using a system developed by Momentus. Through Vigoride's communications and data transfer systems, Orbit Fab will operate the Podracer payload remotely from its Mission Operations Center in Colorado, ensuring real-time control and monitoring of the hosted payload mission. During the Vigoride 7 mission, Momentus and Orbit Fab plan to conduct the first flight demonstration of a hydrazine compatible, Space Systems Command approved RAFTI. Orbit Fab's advanced refueling interface is designed to extend the operational lifespan of satellites, by enabling spacecraft docking and refueling, thereby eliminating the current limitations imposed by onboard fuel reserves. This advancement is expected to significantly reduce costs and improve operational flexibility for satellite operators by mitigating mission constraints caused by fuel shortages. 'We are thrilled to collaborate with Orbit Fab to demonstrate the Podracer and RAFTI payloads to continue to push the boundaries of what's possible in space servicing and space domain awareness,' said Momentus CEO John Rood. 'The new contract with Orbit Fab adds another advanced technology payload to what will be an exciting mission early next year in which Momentus will support several cutting-edge payloads from the U.S. Defense Advanced Research Projects Agency, AFRL, and innovative early-stage space companies.' "We're excited to be working with Momentus as we advance the future of in-space mobility and dynamic space operations,' said Dr. Melissa Sampson, Vice President of Business Development, at Orbit Fab. 'Our collaboration underscores the critical role of on-orbit refueling for increasing satellite maneuverability and mission life. Together, we're pushing the boundaries of space technology and enabling a more agile and sustainable infrastructure in orbit.' This launch marks Momentus' fourth Vigoride mission and its first collaboration with Orbit Fab. In addition to Podracer, Momentus will provide transportation and hosted payload support during the Vigoride 7 mission for several additional commercial and U.S. government customers, including the U.S. Defense Department. As demand for Vigoride missions continues to grow, Momentus is actively planning a follow up mission using its Vigoride 8 OSV. Government and commercial customers interested in launching microsatellites up to 200 kg, cubesats, and hosted payloads in LEO are encouraged to contact the Momentus Commercial Team at sales@ for booking opportunities while space remains available. About Momentus Momentus is a U.S. commercial space company offering satellites, satellite components, and in-space transportation and infrastructure services. The Company offers satellites to support government and commercial customers for missions like communications, missile tracking, and cutting-edge science missions. Momentus offers services such as hosted payloads, support for in-space assembly, on-orbit servicing and refueling, and transportation of satellites to specific orbits. Forward-Looking Statements This press release contains certain statements which may constitute 'forward-looking statements' for purposes of the federal securities laws. Forward-looking statements include, but are not limited to, statements regarding the expected filing of the Company's Form 10-K and Form 10-Q and its management team's expectations, hopes, beliefs, intentions or strategies regarding the future, projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, and are not guarantees of future performance. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Momentus' control. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to risks and uncertainties included under the heading 'Risk Factors' in the Annual Report on Form 10-K filed by the Company on April 9, 2025, as such factors may be updated from time to time in our other filings with the Commission, accessible on the Commission's website at and the Investor Relations section of our website at Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and, except as required by law, the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
The Hill
3 days ago
- The Hill
Experimental Moderna flu shot more effective than approved vaccine, company says
Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial. In a Phase 3 study, the company's mRNA-1010 flu vaccine's efficacy was nearly 27 percent higher for adults 50 and older than a currently available shot. The shot also showed strong efficacy against each of the major influenza strains in the shot including A/H1N1, A/H3N2 and the B/Victoria lineages. Efficacy appeared consistently strong across age groups, flu vaccination status and among people with various risk factors, Moderna said in a statement. The trial enrolled more than 40,800 adults 50 and older from 11 countries. 'The severity of this past flu season underscores the need for more effective vaccines,' said Stephane Bancel, chief executive officer of Moderna. 'An mRNA-based flu vaccine has the potential advantage to more precisely match circulating strains, support rapid response in a future influenza pandemic, and pave the way for COVID-19 combination vaccines.' Seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-25 season, according to the CDC. At least 600,000 Americans were hospitalized last year due to flu-related illness, agency data show. According to the CDC, seasonal flu-related hospitalizations and outpatient visits reached a 15-year high during the 2024-2025 season. [2] More than 600,000 Americans were hospitalized due to flu-related illness last year, leading to substantial direct and indirect costs, as well as widespread disruption to daily life and work After consulting the Food and Drug Administration, Moderna withdrew its application last month for a dual flu and COVID-19 vaccine for adults 50 years old and older. Moderna plans to resubmit the application for the combination vaccine with the new data, according to CNBC. The company also plans to submit the data on the mRNA-1010 shot to U.S. regulators this year.
